Methodology A study was performed on obese patients with EC treated between March and October 2022 in Santa Maria Annunziata Hospital (Florence) using REAL 3D-MIC device (group 1). Prior to surgery, we performed a 3D imaging reconstruction of pelvic lymph nodes used to guide the intraoperatively lymphadenectomy. This group was compared with a historical series of EC patients treated without the 3D model (group 2).

Results The two groups (group1 = 13 patients and group2 = 11 patients) showed homogeneous clinical characteristics. The correspondence between virtual 3D model and real anatomy was analyzed comparing lymph nodes location in virtual 3D model and operative data. We recorded a consistency of 85% (85% for group 1 vs 45% for group 2, p = 0.06). In REAL 3D MIC group we found one nodal EC metastasis and one case of B cells Lymphoma synchronous to EC.

Conclusion REAL-3D MIC could improve the identification of lymph nodes simultaneously with surgery, especially in obese women. Further studies are needed to demonstrate the effectiveness of REAL-3D MIC in lymph nodal mapping.

Disclosures The Authors have no conflicts of interests to declare.

#736 PREDICTION MODEL FOR AORTIC INVOLVEMENT IN ENDOMETRIAL CANCER
Itziar Gonzalez Iriondo*, Marina Matute De Paz, Mikel Gorostiaga Pulgar, Maria Arantza Lekuona, Aitor Muñoz Lamosa. Hospital Universitario Donostia, San Sebastian, Spain
10.1136/ijgc-2023-ESGO.370

Introduction/Background Clinical guidelines for pelvic SLNB in endometrial cancer (EC) do not address the need for evaluation of the aortic region. Isolated aortic involvement in EC is rare. However, in selected groups, the incidence increases, nearly 25%. Moreover, >50% of the cases with pelvic involvement also exhibit aortic involvement. The objective of this study is to develop a prediction model for aortic involvement to guide SLNB, based on preoperative risk factors.

Methodology We evaluated the area under the ROC curve of a prediction model for aortic lymph node involvement using logistic regression, constructed with 376 women who underwent surgery for EC at the University Hospital Donostia (August 2014 - July 2022).

Results The prediction model demonstrated good discrimination, with a c-index of 0.82, and explained 29.33% of the variability in aortic lymph node involvement.

To assess the clinical utility of the model, a decision curve analysis was conducted. Firstly, the net benefit graph was created, not performing aortic lymph node assessment in any patient. It can be observed that the strategy of performing aortic BSGC based on the risk predicted by the prediction model is superior to performing it only in patients with preoperative risks. The use of the model is also superior for the majority of the probability ranges, until the match at 3%. This is because 3% is the minimum predicted probability by the model, so its results are the same as performing BSGC in all cases. Moreover, the net true negatives graph was created, using the strategy of performing aortic BSGC in all patients, as is done at the University Hospital Donostia.

Conclusion The graph demonstrates that using the prediction model to restrict aortic lymph node assessment to patients with a predicted risk above a certain threshold would result in a significant reduction of unnecessary evaluations.

Abstract #736 Figure 1 Analysis of decision curves. Net benefit curves (A) and net reduction in explosions (B). The abscissa axis represents the threshold probability, the limit risk from which the performance of the SLNB would be considered. The net benefit is equivalent to the proportion of true positives in absence of false positives. Thus, for example, the prediction model has a net benefit of around 0.03 at the threshold probability of 10%, which would be equivalent to detecting 3 patients with aortic lymph node involvement without indicating any necessary SLNB for every 100 patients. The maximum value of the net benefit is equal to the prevalence, which occurs when the threshold risk is 0, or at whatever threshold in which classification is perfect (no false positives or false negatives). The net reduction in burst on the other hand is equivalent to the proportion of true negatives in the absence of false negatives. For example, at a threshold probability of 10%, performing SLNB based on the risk estimated according to the prediction model is equivalent to a strategy that reduces the rate of aortic SLNB by around 62% without overlooking any affected aortic SLN.

Disclosures .

#740 EVOLUTION OF AORTIC AND PELVIC DETECTION RATES AFTER VALIDATION OF THE SENTINEL LYMPH NODE BIOPSY IN ENDOMETRIAL CANCER
Marina Matute De Paz*, Itziar Gonzalez Iriondo, Mikel Gorostiaga Pulgar, Arantza Lekuona Artola. Hospital Universitario Donostia, Donostia/San Sebastian, Spain
10.1136/ijgc-2023-ESGO.371

Introduction/Background The systematization of sentinel lymph node technique by a dedicated team implies an improvement in detection rates and a decrease in the acquisition of 'empty' nodes. The number of procedures necessary to acquire this experience has been studied in several publications, demonstrating the importance of the surgeon’s experience to achieve good sensitivity of the technique. Cutoff points have been established between 10 and 40 procedures to reach a plateau.

The improvement in detection rates by abandoning research and validation protocols with sentinel lymph node and lymphadenectomy, and exclusively using sentinel lymph node technique by a dedicated team after a number of procedures exceeding 100–300, including aortic territory, has not been studied.

The objective of this study is to compare changes in detection rates after validation of the sentinel lymph node technique in a high number of procedures at our hospital.
Methodology Retrospective study comparing the rates of overall, aortic, pelvic, and bilateral pelvic detection of a prospective SLNB research cohort in EC in 332 patients, conducted between June 26, 2014, and December 31, 2020, with a validation cohort of 117 patients conducted between January 2021 and January 31, 2023.

Inclusion criteria Patients with pre-surgical early-stage EC undergoing surgical treatment for EC.

Exclusion criteria Age >85 years, frailty criteria, refusal of blood transfusion possibility, suspicion of advanced EC.

Results What is achieved with the implementation of the sentinel lymph node technique is a higher detection rate than with the previous method. Overall, the detection of SLN was 98.8%, compared with 94% previously. Where a higher detection rate is achieved is in the bilateral pelvic SLN, aortic SLN and bilateral aortic + pelvic SLN.

Conclusion The systematization of sentinel lymph node technique by a dedicated team seems to imply an improvement in detection rates and a decrease in the acquisition of ‘empty’ nodes.

Disclosures

#740 Figure 1 Difference in detection rate comparing the old method VS the systematization of sentinel lymph node technique

Abstract #740 Figure 1 Difference in detection rate comparing the old method VS the systematization of sentinel lymph node technique

Abstract #740 Figure 1 Difference in detection rate comparing the old method VS the systematization of sentinel lymph node technique

Conclusion The systematization of sentinel lymph node technique by a dedicated team seems to imply an improvement in detection rates and a decrease in the acquisition of ‘empty’ nodes.

Disclosures

#762 PROGNOSTIC IMPACT OF METABOLIC SYNDROME IN PATIENTS WITH PRIMARY ENDOMETRIAL CANCER: A RETROSPECTIVE BICENTRIC STUDY

Deandra Chetram*, Grace Choong, Andrea Wahner Hendrickson. Mayo Clinic; Rochester, Mn, USA

Introduction/Background CDK 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has promising phase II results in oestrogen receptor (ER)+ recurrent/advanced endometrial cancer (EC) and low grade serous ovarian carcinoma (LGSOC). The purpose of this study is to evaluate characteristics and clinical outcomes of patients with ER+ EC or ovarian cancer (OC) who have received a CDK4/6i+ET at our institution.

Methodology This was a multi-site single centre institution retrospective chart review, including patients diagnosed with EC and OC treated with CDK4/6i+ET between 2016- March 2023 for ≥1 month. Variables obtained included histology, age, and prior ET. Outcomes evaluated included best radiographic response (BRR), time to treatment failure (TTF), and duration of response (DOR).

Results Thirteen patients with EC (8 endometrioid, 4 endometrial stromal sarcoma, 1 adenocarcinoma) and five OC patients were identified (4 LGSOC and 1 mixed low/high grade serous OC).

In EC patients, the TTF was 5.1 months (95% CI 3.8-NR) and 9.8 months (95% CI 7.9-NR) for the endometrioid and ESS group, respectively. EC patients who had CDK 4/6i (n=4) added to ET due to progression had a median DOR of 7.0 months (IQR 5.4–10.4 months), with BRR of stable disease (SD) for all four patients. For EC patients who started CDK4/6i+ET concurrently, their DOR was 11.7 months (IQR 7.7–24 months) with BRR of partial response (PR) (n=1), SD (n=2), and progressive disease (n=3). For OC, the TTF was 13.5 months (95% CI 5.4-not evaluable). All OC patients had CDK 4/6i added to their ET due to progression, with a median DOR on CDK4/6i+ET of 9.0 months (IQR 5.4–13.5 months).

Conclusion Although small sample sizes, this data supports combination therapy in ER+ low grade gynaecologic malignancies including those who have progressed on prior ET. The combination should also be further explored in ESS.

Disclosures Deandra Chetram, MD- No disclosures

Grace Choong, MD- Receipt of honoraria or consultation fees from Targeted Oncology, no other disclosures

Andrea Wahner Hendrickson, MD- Receipt of grants/research supports for Prolynx (clinical trial support) and advisory board for Oxcia (unpaid), otherwise, no other disclosures

This study was not funded by any parties.

#755 EVALUATING THE COMBINATION OF CDK 4/6 INHIBITORS AND ENDOCRINE THERAPY IN ENDOMETRIAL AND OVARIAN CANCERS: A RETROSPECTIVE STUDY

Deandra Chetram*, Grace Choong, Andrea Wahner Hendrickson. Mayo Clinic; Rochester, Mn, USA

10.1136/ijgc-2023-ESGO.372

Introduction/Background CDK 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has promising phase II results in oestrogen receptor (ER)+ recurrent/advanced endometrial cancer (EC) and low grade serous ovarian carcinoma (LGSOC). The purpose of this study is to evaluate characteristics and clinical outcomes of patients with ER+ EC or ovarian cancer (OC) who have received a CDK4/6i+ET at our institution.

Methodology This was a multi-site single centre institution retrospective chart review, including patients diagnosed with EC and OC treated with CDK4/6i+ET between 2016- March 2023 for ≥1 month. Variables obtained included histology, age, and prior ET. Outcomes evaluated included best radiographic response (BRR), time to treatment failure (TTF), and duration of response (DOR).

Results Thirteen patients with EC (8 endometrioid, 4 endometrial stromal sarcoma, 1 adenocarcinoma) and five OC patients were identified (4 LGSOC and 1 mixed low/high grade serous OC).

In EC patients, the TTF was 5.1 months (95% CI 3.8-NR) and 9.8 months (95% CI 7.9-NR) for the endometrioid and ESS group, respectively. EC patients who had CDK 4/6i (n=4) added to ET due to progression had a median DOR of 7.0 months (IQR 5.4–10.4 months), with BRR of stable disease (SD) for all four patients. For EC patients who started CDK4/6i+ET concurrently, their DOR was 11.7 months (IQR 7.7–24 months) with BRR of partial response (PR) (n=1), SD (n=2), and progressive disease (n=3). For OC, the TTF was 13.5 months (95% CI 5.4-not evaluable). All OC patients had CDK 4/6i added to their ET due to progression, with a median DOR on CDK4/6i+ET of 9.0 months (IQR 5.4–13.5 months).

Conclusion Although small sample sizes, this data supports combination therapy in ER+ low grade gynaecologic malignancies including those who have progressed on prior ET. The combination should also be further explored in ESS.

Disclosures Deandra Chetram, MD- No disclosures

Grace Choong, MD- Receipt of honoraria or consultation fees from Targeted Oncology, no other disclosures

Andrea Wahner Hendrickson, MD- Receipt of grants/research supports for Prolynx (clinical trial support) and advisory board for Oxcia (unpaid), otherwise, no other disclosures

This study was not funded by any parties.